Precision peptides, for the people doing the work.
Pharmaceutical-grade compounds with mass-spec validation, sealed chain-of-custody, and the documentation your protocol requires. No theatre. Just clean reagents and clear paperwork.
Lot · EV-024-RSix compounds in active rotation. New lots most weeks.
Each compound is synthesized in our U.S. facility, validated against reference standards, and released only with a signed COA.
Three checks between the synthesizer and the seal.
Every vial leaves the lab with a documented chain of custody. No batch ships without independent verification.
Solid-phase peptide synthesis, in-house.
Compounds are produced in our DEA-licensed U.S. facility using Fmoc-SPPS on a controlled resin. No outsourcing, no overseas intermediates.
HPLC purity. Mass-spec identity.
Each lot is run on reverse-phase HPLC against a reference standard and confirmed by ESI-MS. Endotoxin and residual solvent are quantified.
Signed COA. Sealed shipment.
Lots are lyophilized, sealed under argon, and shipped with a numbered, institution-addressed certificate of analysis. Cold-chain monitored.
Compounded retatrutide, 10mg.
A triple-incretin investigational peptide. Eli Lilly’s LY3437943 synthesized to research grade, lyophilized, sealed under argon, and released with a full chromatographic trace.
Every lot, on the record.
Public release log of the last six lots. Each row links to the signed certificate of analysis, with HPLC and mass-spec traces attached.